期刊文献+

Mobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients 被引量:4

Mobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients
下载PDF
导出
摘要 Objective:To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor(G-CSF) in breast cancer patients.Methods:A total of 57 breast cancer patients were treated with docetaxel 120 mg/m2.When the white blood cell(WBC) count decreased to 1.0×109/L,patients were given G-CSF 5-g/kg daily by subcutaneous injection until the end of apheresis.Peripheral blood mononuclear cells(MNC) were isolated by Cobe Spectra Apheresis System.The percentage of CD34+ cell was assayed by flow cytometry.Results:At a median 6 of days(range 3-8) after the administration of docetaxel,the median WBC count decreased to 1.08×109/L(range 0.20-2.31).The median duration of G-CSF mobilization was 3 days(range 2-7).The MNC collection was conducted 8-12 days(median 10 days) after docetaxel treatment.The median MNC was 5.35×108/kg(range 0.59-14.07),the median CD34+ cell count was 2.43×106/kg(range 0.16-16.69).The CD34+ cell count was higher than 1.00×106/kg in 47 of 57 cases(82.46%) and higher than 2.00×106/kg in 36 cases(63.16%).The CD34+ cell count was higher than 2.00×106/kg in 27 collections(23.68%).The MNC count and the CD34+ cell count were correlated with the bottom of WBC after docetaxel chemotherapy(r=0.364,0.502,P=0.005,0.000).The CD34+ cell count was correlated with the MNC count(r=0.597,P=0.000).The mobilization and apheresis were well tolerated in all patients.Mild perioral numbness and numbness of hand or feet were observed in 3 cases.No serious adverse events were reported.Conclusion:Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients. Objective:To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor(G-CSF) in breast cancer patients.Methods:A total of 57 breast cancer patients were treated with docetaxel 120 mg/m2.When the white blood cell(WBC) count decreased to 1.0×109/L,patients were given G-CSF 5-g/kg daily by subcutaneous injection until the end of apheresis.Peripheral blood mononuclear cells(MNC) were isolated by Cobe Spectra Apheresis System.The percentage of CD34+ cell was assayed by flow cytometry.Results:At a median 6 of days(range 3-8) after the administration of docetaxel,the median WBC count decreased to 1.08×109/L(range 0.20-2.31).The median duration of G-CSF mobilization was 3 days(range 2-7).The MNC collection was conducted 8-12 days(median 10 days) after docetaxel treatment.The median MNC was 5.35×108/kg(range 0.59-14.07),the median CD34+ cell count was 2.43×106/kg(range 0.16-16.69).The CD34+ cell count was higher than 1.00×106/kg in 47 of 57 cases(82.46%) and higher than 2.00×106/kg in 36 cases(63.16%).The CD34+ cell count was higher than 2.00×106/kg in 27 collections(23.68%).The MNC count and the CD34+ cell count were correlated with the bottom of WBC after docetaxel chemotherapy(r=0.364,0.502,P=0.005,0.000).The CD34+ cell count was correlated with the MNC count(r=0.597,P=0.000).The mobilization and apheresis were well tolerated in all patients.Mild perioral numbness and numbness of hand or feet were observed in 3 cases.No serious adverse events were reported.Conclusion:Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2011年第1期49-53,共5页 中国癌症研究(英文版)
基金 supported by a grant from the Beijing Capital Development Foundation for Medical Sciences (No. 2007-2053)
关键词 DOCETAXEL Granulocyte colony-stimulating factor(G-CSF) MOBILIZATION Stem cell Docetaxel Granulocyte colony-stimulating factor(G-CSF) Mobilization Stem cell
  • 相关文献

参考文献22

  • 1Gluz O,Nitz UA,Harbeck N,et al.Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy:results of WSG AM-01 trial.Ann Oncol 2008;19:861-70.
  • 2Zander AR,Schmoor C,Kr6ger N,et al.Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes:overall survival after 6 years of follow-up.Ann Oncol 2008;19:1082-9.
  • 3Nitz UA,Mohrmann S,Fischer J,et al.Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer:results of a multicentre phaseⅢ trial.Lancet 2005;366:1935-44.
  • 4Citron ML,Berry DA,Cirrincione C,et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.J Clin Oncol 2003;21:1431-9.
  • 5Stadtmauer EA,Schneider G,Silberstein LE.Peripheral blood progenitor cell generation and harvesting.Semin Oncol 1995;22:291-300.
  • 6Gomez-Espuch J,Moraleda JM,Ortuno F,et al.Mobilization of hematopoietic progenitor cells with paclitaxel(taxol)as a single chemotherapeutic agent,associated with rhG-CSF.Bone Marrow Transplant 2000;25:231-5.
  • 7Weaver CH,Schwartzberg LS,Birch R,et al.Collection of peripheral blood stem cells following administration of paclitaxel,cyclophosphamide,and filgrastim in patients with breast and ovarian cancer.Biol Blood Marrow Transplant 1997;3:83-90.
  • 8Burris HA 3rd.Single-agent docetaxel(Taxotere)in randomized phase Ⅲ trials.Semin Oncol 1999;26:1-6.
  • 9Burstein HJ,Manola J,Younger J,et al.Docetaxel administered on a weekly basis for metastatic breast cancer.J Clin Oncol 2000;18:1212-9.
  • 10O'Shaughnessy J,Miles D,Vukelja S,et al.Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer:phase Ⅲ trial results.J Clin Oncol 2002;20:2812-23.

同被引文献18

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部